(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 May 2020 (28.05.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/106927 A1

(51) International Patent Classification:
A61K 31/437 (2006.01) *A61P 25/24* (2006.01)
A61K 9/20 (2006.01) *A61B 5/0476* (2006.01)
A61K 31/33 (2006.01) *A61B 5/048* (2006.01)
A61K 31/42 (2006.01) *C07D 413/00* (2006.01)

(21) International Application Number:
PCT/US2019/062554

(22) International Filing Date:
21 November 2019 (21.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/770,287 21 November 2018 (21.11.2018) US

(71) Applicant: **CERTEGO THERAPEUTICS** [US/US]; 3 Bioscience Park Dr., Farmingdale, NY 11735 (US).

(72) Inventors: **OSTEN, Pavel**; 390 Wythe Avenue, Apartment 6D, Brooklyn, NY 11249 (US). **BALDWIN, Kristin**; 2870 4th Avenue, San Diego, CA 92103 (US).

(74) Agent: **SOUTHGATE, Christopher**; Gearhart Law LLC, 41 River Road, Suite 1A, Summit, NJ 07901 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

WO 2020/106927 A1

(54) Title: GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION

FIGURE 1: METHOD FOR WHOLE-BRAIN PHARMACOMAPS REPRESENTING DRUG-EVOKED BRAIN ACTIVATION IN THE MOUSE.



(57) Abstract: Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*